A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure.

Yoshitaka Iwanaga, Yusu Gu, Thomas Dieterle, Cristina Presotto, Piero Del Soldato, Kirk L. Peterson, Ennio Ongini, Gianluigi Condorelli, John Ross

Research output: Contribution to journalArticle

Abstract

Nitric oxide (NO) production is known to be impaired in heart failure. A new compound (NCX 899), a NO-releasing derivative of enalapril was characterized, and its actions were evaluated in Bio 14.6 cardiomyopathic (CM) hamsters with heart failure. The hamsters were randomized to oral treatment for 4 weeks with vehicle (n=11), NCX 899 (NCX, 25 mg/kg, n=10), or enalapril (25 mg/kg, n=10). In the vehicle group, fractional shortening by echocardiography decreased (-23.6+/-2.0%) and LV end-diastolic dimension) increased (+10.9+/-1.0%), whereas fractional shortening increased (+17.5+/-4.4%) in NCX and was unchanged in the enalapril group (both P

Original languageEnglish
Pages (from-to)587-588
Number of pages2
JournalFASEB Journal
Volume18
Issue number3
Publication statusPublished - 2004

    Fingerprint

Cite this

Iwanaga, Y., Gu, Y., Dieterle, T., Presotto, C., Del Soldato, P., Peterson, K. L., Ongini, E., Condorelli, G., & Ross, J. (2004). A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. FASEB Journal, 18(3), 587-588.